Patent application number | Description | Published |
20080214388 | Methods to prepare catalyst compositions comprising small silica support materials - Methods are provided to prepare a catalyst system that includes at least one titanium compound, at least one magnesium compound, at least one electron donor compound, at least one activator compound, and at least one silica support material, the at least one silica support material having a median particle size in the range of from 20 to 50 microns with no more than 10% of the particles having a size less than 10 microns and no more than 10% of the particles having a size greater than 50 microns and average pore diameter of at least ≧220 angstroms. | 09-04-2008 |
20080242821 | Hindered polyalicyclic alkyl catalysts and their use in a gas-phase polymerization reactor - Embodiments of the present invention include a method of polymerizing olefins comprising contacting olefins with a catalyst composition made by the process of combining a hindered polyalicyclic alkyl catalyst precursor with a particulate inorganic oxide for a deposition time greater than 2 hours to form a catalyst composition. Embodiments of the present invention also include catalyst compositions comprising a hindered polyalicyclic alkyl catalyst precursor made by the process of combining the hindered polyalicyclic alkyl catalyst precursor with a particulate inorganic oxide for a deposition time greater than 2 hours to form the catalyst composition. In one embodiment, the hindered polyalicyclic alkyl catalyst precursor is formed by first combining an acid, a compound having the formula RX, and a metal oxide selected from the group consisting of Group 3 to Group 10 oxide compounds to produce a catalyst precursor; characterized in that R is selected from the group consisting of hindered polyalicyclic alkyls, and substituted derivatives thereof, and X is selected from the group consisting of any suitable leaving group. | 10-02-2008 |
20090215970 | Blow Molding Polyethylene Resins - Disclosed herein are various processes, including continuous fluidized-bed gas-phase polymerization processes for making a high strength, high density polyethylene copolymer, comprising (including): contacting monomers that include ethylene and optionally at least one non-ethylene monomer with fluidized catalyst particles in a gas phase in the presence of hydrogen gas at an ethylene partial pressure of 100 psi or more and a polymerization temperature of 120° C. or less to produce a polyethylene copolymer having a density of 0.945 g/cc or more and an ESCR Index of 1.0 or more wherein the catalyst particles are prepared at an activation temperature of 700° C. or less, and include silica, chromium, and titanium. | 08-27-2009 |
20100137533 | HINDERED POLYALICYCLIC ALKYL CATALYSTS AND THEIR USE IN A GAS-PHASE POLYMERIZATION REACTOR - Embodiments of the present invention include a method of polymerizing olefins comprising contacting olefins with a catalyst composition made by the process of combining a hindered polyalicyclic alkyl catalyst precursor with a particulate inorganic oxide for a deposition time greater than 2 hours to form a catalyst composition. Embodiments of the present invention also include catalyst compositions comprising a hindered polyalicyclic alkyl catalyst precursor made by the process of combining the hindered polyalicyclic alkyl catalyst precursor with a particulate inorganic oxide for a deposition time greater than 2 hours to form the catalyst composition. In one embodiment, the hindered polyalicyclic alkyl catalyst precursor is formed by first combining an acid, a compound having the formula RX, and a metal oxide selected from the group consisting of Group 3 to Group 10 oxide compounds to produce a catalyst precursor; characterized in that R is selected from the group consisting of hindered polyalicyclic alkyls, and substituted derivatives thereof, and X is selected from the group consisting of any suitable leaving group. | 06-03-2010 |
20100160580 | Blow molding Polyethylene Resins - Disclosed herein are various processes, including continuous fluidized-bed gas-phase polymerization processes for making a high strength, high density polyethylene copolymer, comprising (including): contacting monomers that include ethylene and optionally at least one non-ethylene monomer with fluidized catalyst particles in a gas phase in the presence of hydrogen gas at an ethylene partial pressure of 100 psi or more and a polymerization temperature of 105° C. or less to produce a polyethylene copolymer having a density of 0.945 g/cc or more and an ESCR Index of 1.0 or more wherein the catalyst particles are prepared at an activation temperature of 700° C. or less, and include silica, chromium, and titanium. | 06-24-2010 |
20140200317 | Methods for Reducing Static Charge of a Catalyst and Methods for Using the Catalyst to Produce Polyolefins - Catalysts and methods for making and using the same are provided. The method for fabricating a catalyst may includes contacting a supported catalyst with a monomer under conditions that reduce an overall charge of the catalyst to less than about 75% of an initial charge of the catalyst. A method for polymerization may include introducing a pre-polymerized catalyst and one or more olefins into a gas phase fluidized bed reactor, operating the reactor at conditions sufficient to produce a polyolefin, wherein the polymerization is carried out in the substantial absence of any continuity additives. | 07-17-2014 |
Patent application number | Description | Published |
20120070342 | LIGHT-ACTIVATED ANTIMICROBIAL ARTICLES AND METHODS OF USE - A light-activated antimicrobial article is disclosed, consisting essentially of an acridine dye covalently bonded without a linking group to a nylon material. The article may be made using electron beam processing. The article in combination with light absorbed by the acridine dye may be used to inhibit the growth of microorganisms. A photosensitive nylon material in which the acridine dye is disposed on the nylon material may also be used. Medical kits that include a light source and an article having the acridine dye are disclosed. | 03-22-2012 |
20120100039 | LIGHT-ACTIVATED ANTIMICROBIAL ARTICLE AND METHOD OF USE - Light-activated antimicrobial devices and articles are disclosed. The devices include a light source and a light-activated antimicrobial article comprising a photosensitizer and a viscoelastic material such as a pressure sensitive adhesive adapted to receive light from the light source. The viscoelastic material may be adapted to transport light by total internal reflection. The photosensitizer may comprise a dye, a metal oxide or a composition that comprises anions that oxidize or react to form a gas. Upon activation of the light source, the photosensitizer absorbs light from the light source such that antimicrobial activity is exhibited. The photosensitizer may be included in the light-activated antimicrobial article or it may be provided as a topical composition that is separate from the article. The light-activated antimicrobial articles and devices may have constructions similar to those of wound dressings. | 04-26-2012 |
20130102728 | CURABLE COMPOSITION COMPRISING DUAL REACTIVE SILANE FUNCTIONALITY - A curable composition comprises (a) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydrosilyl moiety; (b) at least one inorganic or organic compound comprising reactive silane functionality comprising at least one hydroxysilyl moiety, the hydroxysilyl moiety optionally being generated in situ by hydrolysis of at least one hydrosilyl moiety; and (c) at least one base selected from amidines, guanidines, phosphazenes, proazaphosphatranes, and combinations thereof; with the proviso that, when component (a) is an organic polymer, then component (b) is different from component (a) and is not generated in situ by hydrolysis of component (a). | 04-25-2013 |
20140008324 | METHOD FOR MAKING PLASTIC ARTICLES HAVING AN ANTIMICROBIAL SURFACE - Herein are disclosed methods for processing plastic substrate surfaces having inorganic antimicrobial microparticles within. The methods involve providing a plastic substrate having a substrate surface, having inorganic antimicrobial microparticles within the plastic substrate, and exposing the substrate surface to a plasma. | 01-09-2014 |
20140314985 | Platinum-catalyzed Condensation-cure Silicone Systems - Condensation-cure systems comprising at least one silanol-functional polyorganosiloxane and a platinum catalyst are described. The platinum catalysts include Pt(0) complexes, a Pt(II) complexes, and a Pt(IV) complexes. Condensation-cure systems comprising two or more silanol-functional polyorganosiloxanes are described, as are systems comprising a silanol functional polyorganosiloxane in combination with hydride-functional silanes or alkoxy-functional silanes. Articles incorporating cured condensation-cure systems are also disclosed. | 10-23-2014 |
20140329928 | PHOTOACTIVATED, PRECIOUS METAL CATALYSTS IN CONDENSATION-CURE SILICONE SYSTEMS - Photoactivated, precious metal catalysts in combination with condensation-cure silicone systems are described. Curable compositions including hydroxyl-functional polyorganosiloxanes, hydride-functional silanes, and a catalyst comprising a precious metal complexed with an actinic-radiation-displaceable ligand are described. Methods of curing such compositions and the resulting cured compositions are also discussed. | 11-06-2014 |
20140356620 | DUAL CONDENSATION CURE SILICONE - Dual condensation cure silicone systems are described. Such systems include hydroxyl-functional(s), hydride-functional silane(s), platinum catalyst(s) and Ti(W) complex(es). Systems including alkoxy-functional crosslinker(s) are also described. Articles, including adhesive articles included the cured reaction product of such dual condensation cure silicone systems are also described. | 12-04-2014 |
Patent application number | Description | Published |
20090202557 | Compositions and methods for crystallizing antibody fragments - The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes. | 08-13-2009 |
20090312338 | Novel Tricyclic Compounds - The invention provides a compound of Formula (I) | 12-17-2009 |
20110165066 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 07-07-2011 |
20110190489 | Novel Tricyclic Compounds - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 08-04-2011 |
20110311474 | Novel Tricyclic Compounds - The invention provides compounds of Formula (I) and Formula (II) | 12-22-2011 |
20130216497 | NOVEL TRICYCLIC COMPOUNDS - The invention provides compounds of Formula (I) and Formula (II) | 08-22-2013 |
20140099313 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 04-10-2014 |
20140206663 | TRIAZINONE COMPOUNDS - The invention provides a compound of Formula (I) | 07-24-2014 |
20140349970 | NOVEL TRICYCLIC COMPOUNDS - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 11-27-2014 |
Patent application number | Description | Published |
20100292592 | System and method of measuring changes in arterial volume of a limb segment - A medical diagnostic device performs diagnostics for assessing the ability of the arteries to respond to an increase in blood flow. The medical diagnostic device determines relative changes in arterial volume of the limb segment during a time period after a stimulus relative to the arterial volume of the limb segment during a baseline period using the amplitudes or other portions of the component pulse waves (such as early systolic components) of volume pulse waves during the baseline period and after the stimulus. | 11-18-2010 |
20120259236 | SYSTEM AND METHOD OF MEASURING CHANGES IN ARTERIAL VOLUME OF A LIMB SEGMENT - A medical diagnostic device performs diagnostics for assessing the ability of the arteries to respond to an increase in blood flow. The medical diagnostic device determines relative changes in arterial volume of the limb segment during a time period after a stimulus relative to the arterial volume of the limb segment during a baseline period using the amplitudes or other portions of the component pulse waves (such as early systolic components) of volume pulse waves during the baseline period and after the stimulus. | 10-11-2012 |
20140128697 | METHODS FOR DETECTION OF RESPIRATORY EFFORT AND SLEEP APNEA MONITORING DEVICES - A sleep apnea diagnostic system includes a housing that is configured to be attached to near the nose of a patient's face to sense physiological information of a patient. The housing includes sensors to sense the physiological information. The physiological information may be, for example, air flow through the nose or the mouth or both. The physiological information further may be, for example, blood volume. The sleep apnea diagnostic system includes at least one processor in the housing or external to the housing or both to analyze the physiological information to determine whether the patient has experienced irregular or abnormal respiratory activity and to detect respiratory effort. The analysis may be real time or delayed. | 05-08-2014 |
20140213913 | METHODS FOR DETECTION OF RESPIRATORY EFFORT AND SLEEP APNEA MONITORING DEVICES - A sleep apnea diagnostic system includes a housing that is configured to be attached to near the nose of a patient's face to sense physiological information of a patient. The housing includes sensors to sense the physiological information. The physiological information may be, for example, air flow through the nose or the mouth or both. The physiological information further may be, for example, blood volume. The sleep apnea diagnostic system includes at least one processor in the housing or external to the housing or both to analyze the physiological information to determine whether the patient has experienced irregular or abnormal respiratory activity and to detect respiratory effort. The analysis may be real time or delayed. | 07-31-2014 |